Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

Core Insights - Lifecore Biomedical has signed an agreement to transfer commercial manufacturing of a leading injectable pharmaceutical product to its facilities, becoming the supplier of choice for this product after meeting regulatory requirements [1][2] - This marks the second agreement with the same multinational organization in recent months, indicating Lifecore's growing reputation for quality and reliability in sterile injectables [1][2] - Additionally, Lifecore has entered into a pre-clinical formulation development agreement with an early-stage biotech company, further expanding its early-stage program pipeline [2] Company Strategy - The commercial site transfer is part of Lifecore's growth strategy to expand its CDMO business and build long-term partnerships with leading global pharmaceutical companies [2] - The new agreement will broaden Lifecore's commercial customer base and increase capacity utilization while allowing entry into new modalities [2] - Lifecore aims to capitalize on strong industry momentum and strengthen its position as a trusted U.S.-based CDMO partner [3] Company Background - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of expertise and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [4]